Gilead Sciences (NASDAQ:GILD) was upgraded by stock analysts at Vetr from a “buy” rating to a “strong-buy” rating in a report issued on Monday. The firm presently has a $91.25 target price on the biopharmaceutical company’s stock. Vetr‘s price target suggests a potential upside of 12.74% from the company’s previous close.
A number of other analysts have also recently issued reports on GILD. JPMorgan Chase & Co. set a $85.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, October 25th. BMO Capital Markets cut their target price on shares of Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a research note on Friday, October 27th. Maxim Group restated a “hold” rating on shares of Gilead Sciences in a research note on Friday, October 27th. Mizuho set a $77.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Sunday, October 29th. Finally, Argus cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and raised their target price for the stock from $73.25 to $73.77 in a research note on Monday, November 13th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $87.04.
Gilead Sciences (NASDAQ GILD) opened at $80.94 on Monday. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $89.54. The company has a market cap of $105,700.00, a PE ratio of 23.26, a PEG ratio of -1.85 and a beta of 1.22. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.55 and a quick ratio of 3.48.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.11. The company had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The company’s quarterly revenue was down 18.7% on a year-over-year basis. During the same quarter last year, the firm posted $2.70 EPS. sell-side analysts expect that Gilead Sciences will post 6.24 earnings per share for the current year.
In other news, insider John C. Martin sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total value of $3,681,000.00. Following the completion of the transaction, the insider now directly owns 3,046,766 shares in the company, valued at approximately $224,302,912.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $74.98, for a total transaction of $5,498,508.34. Following the completion of the transaction, the insider now owns 3,070,099 shares of the company’s stock, valued at $230,196,023.02. The disclosure for this sale can be found here. Insiders sold a total of 418,333 shares of company stock valued at $32,742,108 over the last 90 days. Corporate insiders own 1.30% of the company’s stock.
Several large investors have recently modified their holdings of the company. FMR LLC grew its holdings in shares of Gilead Sciences by 1.1% during the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after purchasing an additional 258,005 shares during the last quarter. Macquarie Group Ltd. grew its holdings in shares of Gilead Sciences by 26.6% during the 3rd quarter. Macquarie Group Ltd. now owns 479,332 shares of the biopharmaceutical company’s stock valued at $38,836,000 after purchasing an additional 100,741 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Gilead Sciences by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after purchasing an additional 2,148,697 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Gilead Sciences by 0.7% during the 2nd quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after purchasing an additional 116,780 shares during the last quarter. Finally, Toronto Dominion Bank grew its holdings in shares of Gilead Sciences by 19.0% during the 2nd quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock valued at $33,445,000 after purchasing an additional 75,364 shares during the last quarter. Institutional investors own 75.71% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.thelincolnianonline.com/2018/02/21/gilead-sciences-gild-lifted-to-strong-buy-at-vetr.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.